HSE detects high-risk cannabinoids in vape products

The Health Service Executive (HSE) in Ireland has identified high-risk cannabinoids in vapes, vape juice and other products, such as edibles, sold in shops and on the illicit market. Synthetic cannabinoids, man-made substances designed to mimic the effects of cannabis, have been linked to serious health issues, including loss of consciousness, severe intoxication, and psychosis across various counties.

This year, the HSE laboratory analyzed 76 vapes, finding 28 contained hexahydrocannabinol (HHC) or related semi-synthetic cannabinoid compounds, eight contained potent synthetic cannabinoids, 10 had acetate containing a compound linked to lung disease, 12 contained cannabis or related compounds, and 41 contained cannabidiol. Responsible Vaping Ireland, representing over 3,200 independent vape retailers, expressed concern over the growth of unregulated products in the illicit market and called for government enforcement against rogue operators.

Professor Matthew Sadlier, President of the Irish Medical Organisation, advocated for primary prevention, emphasizing the severe mental health consequences and the need to change public perception. Colin O Gara, head of Addiction Services at St John of God University Hospital, noted issues with labeling, stating that some products were labelled as nicotine but contained dangerous cannabinoids.

He highlighted the potential for young people to purchase these harmful substances in vape shops. Dr Brian O Mahony, Senior Registrar in Psychiatry at St Vincent's Hospital, warned of long-term psychological consequences, including schizophrenia or bipolar disorder, if untreated.